Core Viewpoint - Purple Biotech Ltd. has regained compliance with Nasdaq's minimum bid price requirement, allowing for continued listing on the Nasdaq Capital Market [2]. Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing a next-generation immunotherapy platform aimed at maximizing anti-cancer potency while minimizing toxicity [3]. - The company is advancing its lead program, CAPTN-3, which utilizes masked tri-specific antibodies to target tumors and engage T cells and NK cells [3]. - The lead candidate, IM1240, is progressing towards clinical trials, while the second candidate, IM1305, is in preclinical development [3]. - The pipeline includes additional clinical-stage assets such as CM24, a CEACAM1-blocking antibody, and NT219, a dual IRS1/2 and STAT3 inhibitor, both of which are in Phase 2 studies for various cancers [3].

Company Leadership Transition - Gil Efron will step down as CEO of Purple Biotech Ltd. effective August 2026 due to health considerations, but will continue to lead corporate development and remain on the Board of Directors [1][2] - The Board of Directors has initiated a search for a new CEO with experience in leading innovative biotechnology companies [2][3] - Efron has served in senior leadership roles for eight years, including as CFO and CEO, and has been instrumental in the company's strategic repositioning around the CAPTN-3 platform [3][4] CAPTN-3 Platform Overview - CAPTN-3 is Purple Biotech's lead program, featuring capped tri-specific antibodies that target tumor-associated antigens while engaging T cells and NK cells [4][5] - The proprietary capping technology confines immune activation to the tumor microenvironment, significantly expanding the therapeutic window compared to conventional T-cell engagers [4][5] - The lead candidates, IM1240 and IM1305, are in preclinical development, with IM1240 advancing toward clinical trials [5][6] Company Background - Purple Biotech Ltd. is a clinical-stage company focused on developing next-generation immunotherapy platforms aimed at maximizing anti-cancer potency while minimizing toxicity [5][6] - The company is headquartered in Rehovot, Israel, and is advancing its lead program, CAPTN-3, alongside additional clinical-stage assets [6]